BEIJING China’s vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country’s intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday.
The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s Hong Kong shares rose around 14% in Monday’s morning session. Its Shanghai shares rose by 6.6% as of midday.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment